Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile

In November 2019, The World Health Organization (WHO) issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF), a Phlebovirus with a three segmented genome, in both humans and ruminants. The TPPs contained r...

Descripción completa

Detalles Bibliográficos
Autores principales: Monath, Thomas P., Kortekaas, Jeroen, Watts, Douglas M., Christofferson, Rebecca C., Desiree LaBeaud, Angelle, Gowen, Brian, Peters, Clarence J., Smith, Darci R., Swanepoel, Robert, Morrill, John C., Ksiazek, Thomas G., Pittman, Phillip R, Bird, Brian H., Bettinger, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176985/
https://www.ncbi.nlm.nih.gov/pubmed/32337506
http://dx.doi.org/10.1016/j.jvacx.2020.100060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176985/
https://www.ncbi.nlm.nih.gov/pubmed/32337506
http://dx.doi.org/10.1016/j.jvacx.2020.100060

Ejemplares similares